Clinical trial · Observational
Predictive Value of FDG PET/CT, DWI and DCE-MRI Scans for Non-small Cell Lung Cancer Patients Receiving Chemotherapy
Prediction of Chemotherapy Response and Patient Prognosis in Non-small Cell Lung Cancer: Dynamic Contrast-enhanced MRI and Diffusion-weighted Imaging Versus Volume-based Parameter of 18F-FDG PET
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In this prospective study, the investigators will evaluate and compare the usefulness of functional and volumetric informations obtained by 18F-FDG PET and MRI before and after the palliative chemotherapy with the aim of predicting tumor response and prognosis in patients with advanced Non-small Cell Lung Cancer (NSCLC).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- DWI, DCE-MRI, and FDG PET as early predictor for response and prognosis
- timeFrame
- one year
- description
- The primary endpoint of this study is the prediction of one-year overall survival by monitoring the metabolic and functional responses of the tumor following one cycle of chemotherapy.
Secondary outcomes (2)
- measure
- Correlation among DWI, DCE-MRI, and FDG PET and relationship with prognosis
- timeFrame
- one year
- description
- Correlation among metabolic response, functional response on MRI, and standard anatomic response using the RECIST criteria
- measure
- Correlation among DWI, DCE-MRI, and FDG PET and relationship with prognosis
- timeFrame
- one year
- description
- (i) the correlation among metabolic response, functional response on MRI, and standard anatomic response using the RECIST criteria (ii) the correlation between functional response (metabolic and MR parameters) and progression-free survival (iii) comparison between the predictive values of FDG-PET and MRI for one-year overall survival.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically proven NSCLC * Newly diagnosed Stage stage IV * Participant is being considered for the chemotherapy with EGFR TKI as a first line therapy * At least one measurable primary or other intrathoracic lesion \>= 2cm, according to RECIST * Performance status of 0 to 2 on the ECOG scale * Age 18 years or older * Able to tolerable PET/CT and MRI imaging required by protocol * Able to give study-specific informed consent Exclusion Criteria: * Pure bronchioloalveolar cell carcinoma histology * Thoracic radiotherapy, lung surgery or chemotherapy within three months prior to inclusion in the study * Poorly controlled diabetes * Prior malignancy
References
Publications (0)
Data not yet available